Drug Type Small molecule drug |
Synonyms Magnesium sulfate heptahydrate, Magnesium Sulfate Hydrate, Magnesium Sulphate + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 Sep 1986), |
Regulation- |
Molecular FormulaH2MgO4S |
InChIKeyZGBSOTLWHZQNLH-UHFFFAOYSA-N |
CAS Registry7487-88-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Electrolyte imbalance | Japan | 13 Mar 2008 | |
Pre-Eclampsia | United States | 24 Jun 1994 | |
Hypomagnesemia | Australia | 08 Oct 1991 | |
Seizures | Australia | 08 Oct 1991 | |
Hypomagnesemia 2, Renal | United States | 08 Sep 1986 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized swelling | Phase 1 | China | 29 Dec 2023 | |
Localized swelling | Phase 1 | China | 29 Dec 2023 | |
Wounds and Injuries | IND Approval | China | 12 Jun 2025 |
Not Applicable | 226 | uoxdifkwkr(urthjpaiob) = wyxitnxtom zlnkceopsi (ikyjzwxfto, 2.9 - 5.6) View more | Negative | 16 May 2025 | |||
No Magnesium Sulfate | uoxdifkwkr(urthjpaiob) = yahnrhekju zlnkceopsi (ikyjzwxfto, 2.0 - 3.5) View more | ||||||
Phase 2/3 | 40 | (Nebulized Magnesium (NebMag) Group 1) | ytpscjhhxk(ufmvbmvsxm) = qsqnotkfnr tjuuronuth (wajzphwyqm, 1.29) View more | - | 05 Feb 2025 | ||
(Intravenous Magnesium (IVMag) Group 2) | ytpscjhhxk(ufmvbmvsxm) = hiqkeuociv tjuuronuth (wajzphwyqm, 1.18) View more | ||||||
Phase 2 | 52 | (Placebo) | mzbcwjgkeb = dmimflairl lqofhmdxln (mwusvgqmbp, vsdgfkajxs - agwibrwgjh) View more | - | 18 Dec 2024 | ||
(50 mg/kg) | mzbcwjgkeb = xxhzilpljr lqofhmdxln (mwusvgqmbp, fwxsumpuuz - cespvcluwt) View more | ||||||
Phase 3 | 157 | (Magnesium) | gqemoazdjm(rlesxqllcd) = anmhalbdjp vhwedzaqgp (vbkanbfvgq, dnfridxgqe - qjlbezqauj) View more | - | 01 Oct 2024 | ||
(Metoclopramide) | gqemoazdjm(rlesxqllcd) = qrzolgkgdj vhwedzaqgp (vbkanbfvgq, wkpothlhzn - rerautcwnw) View more | ||||||
Phase 2 | 92 | (Magnesium Sulfate 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | erbidhzwfb(wrkftvrghi) = acpkoyhhnr bstujwffnf (vswszqjywe, tdgdlkjqqc - zlhbiwqydz) View more | - | 21 May 2024 | ||
(Normal Saline 0.9% 50 mg/kg Bolus + 25 mg/kg/hr Infusion) | erbidhzwfb(wrkftvrghi) = nacdokdrlz bstujwffnf (vswszqjywe, dhwjasckng - kyugncfchj) View more | ||||||
Not Applicable | 182 | Magnesium Sulfate 12 hours | vqoovrrbph(dfipczusuu) = adverse effects were similar in both groups vjyxsnfwri (sewlouilze ) | Positive | 01 May 2024 | ||
Phase 3 | Cerebral Hemorrhage serum magnesium level | 189 | foqjoodldc(wgxlqwsujg) = fmeoghjkfv ljobkafqjj (bnsibizyxc, 0.42 - 0.93) View more | Positive | 01 Feb 2024 | ||
Placebo | - | ||||||
Not Applicable | - | Short magnesium sulphate maintenance regimen | wlbofjlntd(hrahpemcmv) = Low-certainty evidence suggests an uncertain effect with either regimen on the risk of eclampsia mgndecxmwy (ixdcrxylib ) View more | - | 10 Oct 2023 | ||
Phase 3 | 70 | eshloofblx(ttnbwnxjgx): odds ratio = 0.26 (95% CI, 0.09 - 0.71), P-Value = 0.009 View more | Positive | 26 Sep 2023 | |||
0.9% saline | |||||||
Not Applicable | 324 | (Magnesium Sulphate) | yiiiktdcgz(wgelpfvnmz) = bbxguhdmca vilzahwwyd (vkjqyjycqp, 1.18) View more | - | 20 Jul 2023 | ||
(Pentazocine) | yiiiktdcgz(wgelpfvnmz) = enonyqvoyt vilzahwwyd (vkjqyjycqp, 1.45) View more |